Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram in treatment-resistant depression after venlafaxine nonresponse
2004-004625-96Phase 3Completed
- Sponsor
- Group for the Study of Resistant Depression (GSRD), Head: Prof. Julien Mendlewicz
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of escitalopram in treatment-resistant depression (TRD) and major depressive disorder (MDD), sponsored by Group for the Study of Resistant Depression (GSRD), Head: Prof. Julien Mendlewicz. Primary endpoints: Mean change in MADRS total score from baseline, Safety and tolerability of escitalopram and 1 more. Started Sep 2005; status: completed.
02
Drugs
escitalopram
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2004-004625-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004625-96.